ARHGAP19 inhibitors constitute a distinctive category within the realm of chemical compounds that have garnered considerable scientific interest due to their capability to modulate the activity of ARHGAP19, also known as oligophrenin-1. ARHGAP19 is a GTPase-activating protein that exerts regulatory control over small GTPases, pivotal players in cellular signaling and cytoskeletal dynamics. These inhibitors encompass a diverse array of molecules, each possessing distinct structural attributes and mechanisms of action that enable them to interfere with ARHGAP19's functioning. Structurally, ARHGAP19 inhibitors exhibit a broad spectrum of chemical scaffolds, ranging from small organic molecules to potential natural compounds, which offer them the capacity to interact with the active sites and binding pockets of ARHGAP19. Mechanistically, these inhibitors exert their effects through various pathways. Some compounds directly bind to ARHGAP19, hindering its catalytic activity and consequently altering the regulation of GTPases. Others might influence the interactions between ARHGAP19 and its molecular partners, leading to downstream effects on cellular processes that depend on GTPase signaling.
The study of ARHGAP19 inhibitors has illuminated the intricate molecular mechanisms through which ARHGAP19 modulates cellular behavior. Researchers have diligently explored the three-dimensional structure of ARHGAP19, facilitating the design and optimization of inhibitors that can effectively target specific regions of the protein. Additionally, these inhibitors have been subjected to comprehensive biochemical and biophysical investigations to unravel the nuances of their interactions with ARHGAP19 and to delineate the precise modes of action they employ to hinder its function. The realm of ARHGAP19 inhibitors continues to evolve, with ongoing research continually uncovering novel insights into their mechanisms of action and potential applications. As our understanding of ARHGAP19's role in cellular processes deepens, the development and refinement of inhibitors within this chemical class hold the potential to expand our understanding of fundamental cellular mechanisms. These compounds could serve as valuable tools for dissecting intricate cellular processes that hinge on GTPase regulation, ultimately contributing to the advancement of scientific knowledge in diverse fields.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Similar to fasudil, Y-27632 is a selective inhibitor of ROCK kinases. Its inhibition of ROCKs can impact the downstream effects of ARHGAP19 on cellular processes like actin cytoskeleton regulation. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
This cholesterol-lowering agent has been found to exert pleiotropic effects, including the modulation of small GTPase signaling pathways. By altering the activity of these GTPases, simvastatin could potentially affect ARHGAP19-regulated processes. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin exhibit effects on cellular signaling pathways that intersect with ARHGAP19's activities, potentially through the modulation of small GTPases. | ||||||
Raloxifene | 84449-90-1 | sc-476458 | 1 g | $802.00 | 3 | |
Raloxifene, an estrogen receptor modulator, has been shown to impact Rho GTPase activity and cellular processes connected to ARHGAP19's functions. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Tipifarnib inhibits prenyltransferases, enzymes involved in modifying small GTPases, can indirectly influence ARHGAP19-controlled pathways by affecting the post-translational modifications of GTPases. | ||||||
Lonafarnib | 193275-84-2 | sc-482730 sc-482730A | 5 mg 10 mg | $173.00 $234.00 | ||
Farnesyltransferase inhibitors, such as Lonafarnib, can disrupt the prenylation of Rho GTPases, leading to altered cellular responses influenced by ARHGAP19. | ||||||
Combrestatin A4 | 117048-59-6 | sc-204697 sc-204697A | 1 mg 5 mg | $46.00 $81.00 | ||
This compound exhibits anti-tumor effects and has been found to impact small GTPase signaling pathways, which could intersect with ARHGAP19's regulatory mechanisms. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
In addition to statins, inhibitors of HMG-CoA reductase (the enzyme targeted by statins) might indirectly affect ARHGAP19-mediated cellular processes by influencing the mevalonate pathway and thus impacting GTPase modification. | ||||||
Farnesyl thiosalicylic acid | 162520-00-5 | sc-205322 sc-205322A | 1 mg 5 mg | $61.00 $82.00 | 15 | |
Salirasib is a Ras inhibitor that interferes with the activity of Ras GTPases, which are closely related to the Rho family of GTPases. Its mechanism of action could have implications for ARHGAP19-regulated pathways. | ||||||